In order to investigate whether circulating TGF-β ligand levels differ between controls and ALS patients, serum levels of TGF-β1 and TGF-β2 were determined via electrochemiluminescence. This evidence concerns the gene TGFB2 and amyotrophic lateral sclerosis.